2Spudich S, Gisslen M, Hagberg L, et al. Central nervous sys tern immune activation characterizes primary human immunode- ficiency virus 1 infection even in participants with minimal cere- hrospinal fluid viral burden[J]. Journal of Infectious Diseases, 2011, 204(5) :753-760.
3Nau R, Srgel F, Eiffert H. Penetration of drugs through theblood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections[J]. Clinical microbiology re- views, 2010, 23(4):858-883.
